US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Adlai Nortye Ltd.

0.1835

0.0000

Volume:- -

Turnover:- -

Market Cap:12.58M

PE:1.53

High:0.1835

Open:0.1835

Low:0.1835

Close:0.1835

52wk High:0.1835

52wk Low:0.1835

Shares:68.57M

Float Shares:3.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1200

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Jefferies Initiates Coverage on Adlai Nortye With Buy Rating, $31 Price Target

MT Newswires Live

Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained

Adlai Nortye Price Target Announced at $49.00/Share by LUCID Capital Markets

Adlai Nortye Doses First Patient in Phase I Trial for Solid Tumors

MT Newswires Live

Adlai Nortye doses first patient in AN4035 trial

Adlai Nortye assumed with a Buy at Lucid Capital

Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says

MT Newswires Live

Oppenheimer Sticks to Their Buy Rating for Adlai Nortye Ltd. Sponsored ADR (ANL)

Major Insider Move Shakes Up Adlai Nortye’s Market Narrative

Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes

Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M

Benzinga Earnings

Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M

MT Newswires Live

Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated

Adlai Nortye Receives Ethics Approval to Begin Phase 1 Trial of Cancer Drug AN4035

MT Newswires Live

Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway

Alnylam Expands Into Obesity With New Phase 1 Trial for ALN-6222

Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald

Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained

Adlai Nortye Doses First US Patient in Weekly Arm of Phase 1 AN9025 Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/ALN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALN\",,,,,undefined,":{"symbol":"ALN","market":"US","secType":"STK","nameCN":"Adlai Nortye Ltd.","latestPrice":0.1835,"timestamp":1788984000000,"preClose":0.1835,"halted":9,"volume":0,"delay":0,"changeRate":0,"floatShares":3000000,"shares":68570000,"eps":0.12,"marketStatus":"Pre-Mkt","change":0,"latestTime":"09-10 09:18:04 EDT","open":0.1835,"high":0.1835,"low":0.1835,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.12,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1692331200000,"exchange":"NASDAQ","adjPreClose":0.1835,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALN\",,,,,undefined,":{"symbol":"ALN","floatShares":3000000,"roa":"--","roe":"--","lyrEps":0,"shares":68570000,"dividePrice":0,"high":0.1835,"amplitude":0,"preClose":0.1835,"low":0.1835,"week52Low":0.1835,"pbRate":"--","week52High":0.1835,"institutionHeld":0,"latestPrice":0.1835,"eps":0.12,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.12,"open":0.1835},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666593870","title":"Jefferies Initiates Coverage on Adlai Nortye With Buy Rating, $31 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666593870","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666593870?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:06","pubTimestamp":1789041975,"startTime":"0","endTime":"0","summary":"Adlai Nortye (ANL) has an average rating of buy and mean price target of $28.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371875","title":"Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371875","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371875?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:55","pubTimestamp":1788882921,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR and keeping the price target at $20.00. Jo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-buy-rating-reiterated-as-ras-targeted-pipeline-advances-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-buy-rating-reiterated-as-ras-targeted-pipeline-advances-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320246","title":"Adlai Nortye Price Target Announced at $49.00/Share by LUCID Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320246","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320246?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:16","pubTimestamp":1788869760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANL/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665270943","title":"Adlai Nortye Doses First Patient in Phase I Trial for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2665270943","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665270943?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:53","pubTimestamp":1788868406,"startTime":"0","endTime":"0","summary":"Adlai Nortye  has dosed the first patient in Australia in a global Phase I trial of AN4035 as a potential treatment for CEACAM5-enriched, RAS-addicted solid tumors, the company said Tuesday.The company also received a \"Study-May-Proceed\" letter from the US Food and Drug Administration on its investigational new drug application for AN4035, clearing the way to expand the trial to the US, the company said.The Phase I trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AN4035 as both a monotherapy and in combination with cetuximab, the company said.Shares of the company were up 1.3% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALN","LU2133065610.SGD","IE00BZ199S13.USD","ANL","BK7104","ANL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327895","title":"Adlai Nortye doses first patient in AN4035 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327895","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327895?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:15","pubTimestamp":1788866121,"startTime":"0","endTime":"0","summary":"Adlai Nortye (ANL) announced that the first patient has been dosed with AN4035 in Australia, initiating the global Phase I trial in patients with C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adlai-nortye-doses-first-patient-in-an4035-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adlai-nortye-doses-first-patient-in-an4035-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANL","BK4139","ALN","LU2133065610.SGD","IE00BZ199S13.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665032258","title":"Adlai Nortye assumed with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2665032258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665032258?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:45","pubTimestamp":1788864325,"startTime":"0","endTime":"0","summary":"Lucid Capital assumed coverage of Adlai Nortye (ANL) with a Buy rating and price target of $49, up from $46. The firm believes AN9025, an oral pan-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adlai-nortye-assumed-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adlai-nortye-assumed-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2133065610.SGD","BK4596","BK4551","LCIZ","BK4555","ALN","IE00BZ199S13.USD","LCID","BK4139","BK4099","ANL","LCDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664135884","title":"Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664135884","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664135884?lang=en_us&edition=fundamental","pubTime":"2026-09-04 23:09","pubTimestamp":1788534579,"startTime":"0","endTime":"0","summary":"Adlai Nortye  stands to benefit from the GSK -Hutchmed  deal, which validates growing interest in targeted KRAS therapies, Oppenheimer said in a note emailed Friday.Hutchmed said Thursday its unit licensed rights to GSK to develop and commercialize experimental cancer treatment HMPL-A830 outside Greater China.HMPL-A830 is an EGFR-targeted antibody-drug conjugate carrying a KRAS inhibitor payload. The deal highlights increasing interest in targeted approaches that aim to improve the therapeutic index of RAS-pathway inhibition, Oppenheimer analysts said.Adlai Nortye's approach is differentiated, with AN9025 already in the clinic and data expected in H1 2027. AN4035 uses a pan-RAS inhibitor payload with a CEACAM5-targeting antibody, which could provide advantages in breadth, durability, and target selection, the analysts added.The deal should improve \"investor awareness of comparable RAS-focused platforms and reinforce the strategic value embedded within Adlai Nortye's differentiated RAS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1720051108.HKD","ONX","BK4139","LU1854104046.USD","BK4532","LU1978683503.SGD","LU1983260115.SGD","LU2357305700.SGD","LU1861219969.SGD","BK4007","ON","ALN","GSK","LU0124384867.USD","LU0724618433.USD","BK4605","BK4588","BK4512","BK4141","LU1861214812.USD","IE00BZ199S13.USD","LU1861215975.USD","ONG","LU1861220033.SGD","GSK.UK","BK4531","HCM","IE00BD6J9T35.USD","LU2133065610.SGD","BK4585","BK7104","LU1720051017.SGD","LU2360107325.USD","ANL","LU1829250122.USD","GSKH","LU1548497426.USD","IE00BFMHRM44.USD","LU1854103824.USD","LU2298322129.HKD","LU0348723411.USD","ANL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004867","title":"Oppenheimer Sticks to Their Buy Rating for Adlai Nortye Ltd. Sponsored ADR (ANL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662004867?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:55","pubTimestamp":1787835325,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR today and set a price target of $32.00. Olson covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAPH","AADR","ANL","ARMH","CVY","ALN","DIVL","APIE","DINT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662248477","title":"Major Insider Move Shakes Up Adlai Nortye’s Market Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662248477","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662248477?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:13","pubTimestamp":1787796782,"startTime":"0","endTime":"0","summary":"New insider activity at Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has taken place on August 26, 2026. Adlai Nortye Ltd. Sponsored ADR has seen ins...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-move-shakes-up-adlai-nortyes-market-narrative-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-move-shakes-up-adlai-nortyes-market-narrative-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2133065610.SGD","IE00BZ199S13.USD","ALN","DIVL","ARMH","APIE","SAPH","BK4139","CVY","ANL","AADR","DINT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662740712","title":"Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740712","media":"TIPRANKS","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662740712?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:27","pubTimestamp":1787750843,"startTime":"0","endTime":"0","summary":"Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has issued an update. Adlai Nortye Group Ltd. has called an Extraordinary General Meeting of shareholder...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adlai-nortye-calls-september-extraordinary-meeting-to-authorize-major-share-issuance-and-board-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adlai-nortye-calls-september-extraordinary-meeting-to-authorize-major-share-issuance-and-board-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVY","ANL","AADR","DIVL","LU2133065610.SGD","APIE","BK4139","SAPH","ARMH","ALN","DINT","IE00BZ199S13.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121302","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121302?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:40","pubTimestamp":1786740009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-us-physical-therapy-usph-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-us-physical-therapy-usph-and-adlai-nortye-ltd-sponsored-adr-anl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2133065610.SGD","ANL","CVY","DIVL","BK4139","BK4185","APIE","HCSG","SAPH","LU0128526141.USD","XLV","BK4581","BK4137","BK4585","ALN","BK4588","DINT","XBI","USPH","IE00BZ199S13.USD","AADR","LU0106261612.USD","LABU","ARMH","LU0029874061.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659459061","title":"Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M","url":"https://stock-news.laohu8.com/highlight/detail?id=2659459061","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659459061?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:22","pubTimestamp":1786706547,"startTime":"0","endTime":"0","summary":"Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year.  The company reported $13.056 million in sales","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61204389/adlai-nortye-h1-eps-0-04-0-19-yoy-sales-13-056m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659414301","title":"Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2659414301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659414301?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:05","pubTimestamp":1786705552,"startTime":"0","endTime":"0","summary":"Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANL","ANL.AU","ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303170","title":"Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303170","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303170?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:55","pubTimestamp":1785776118,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Adlai Nortye Ltd. Sponsored ADR. The associated price target remain...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-at-buy-as-first-in-class-rasica-adc-enters-clinic-20-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-at-buy-as-first-in-class-rasica-adc-enters-clinic-20-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656760873","title":"Adlai Nortye Receives Ethics Approval to Begin Phase 1 Trial of Cancer Drug AN4035","url":"https://stock-news.laohu8.com/highlight/detail?id=2656760873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656760873?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:11","pubTimestamp":1785759089,"startTime":"0","endTime":"0","summary":"Adlai Nortye  said it has submitted a clinical trial notification to Australia's Therapeutic Goods Administration and received approval from the Human Research Ethics Committee to begin a phase 1 trial of AN4035.The global trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AN4035, both as a monotherapy and in combination with cetuximab, in patients with CEACAM5-enriched, RAS-addicted solid tumors.AN4035 is a CEACAM5-targeting antibody-drug conjugate built around a pan-RAS inhibitor payload.The company expects to begin dosing patients in the second half of the year.Adlai Nortye also said it is filing investigational new drug applications for AN4035 with the US Food and Drug Administration and China's National Medical Products Administration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0124384867.USD","LU1861220033.SGD","BK4141","LU1854104046.USD","LU2357305700.SGD","LU1978683503.SGD","ON","ANL.AU","LU1861214812.USD","ALN","LU1861215975.USD","BK4605","LU1983260115.SGD","ANL","IE00BZ199S13.USD","LU1548497426.USD","BK7104","IE00BFMHRM44.USD","LU1861219969.SGD","LU1854103824.USD","IE00BD6J9T35.USD","BK4585","LU2133065610.SGD","LU1720051017.SGD","LU2298322129.HKD","LU1720051108.HKD","LU2360107325.USD","BK4588","BK4139","BK4512","LU0348723411.USD","LU0724618433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049878","title":"Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654049878?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:55","pubTimestamp":1785164125,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Boris Peaker has maintained their bullish stance on ANL stock, giving a Buy rating on July 16. Boris Peaker has given his Buy ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-with-buy-on-differentiated-ras-targeting-pipeline-adc-strategy-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-initiated-with-buy-on-differentiated-ras-targeting-pipeline-adc-strategy-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ199S13.USD","ADC","BK4231","ANL","LU2133065610.SGD","BK4080","ALN","BK4139","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654250036","title":"Alnylam Expands Into Obesity With New Phase 1 Trial for ALN-6222","url":"https://stock-news.laohu8.com/highlight/detail?id=2654250036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654250036?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:33","pubTimestamp":1784910836,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Randomized, Double-blind,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylam-expands-into-obesity-with-new-phase-1-trial-for-aln-6222?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylam-expands-into-obesity-with-new-phase-1-trial-for-aln-6222?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652918902","title":"Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2652918902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652918902?lang=en_us&edition=fundamental","pubTime":"2026-07-20 17:06","pubTimestamp":1784538376,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Adlai Nortye Ltd. Sponsored ADR on July 16. The company’s shares closed last Friday ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adlai-nortye-ltd-sponsored-adr-anl-receives-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adlai-nortye-ltd-sponsored-adr-anl-receives-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAPH","ALN","APIE","BK4139","CVY","DINT","DIVL","AADR","IE00BZ199S13.USD","ANL","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652266114","title":"Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2652266114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652266114?lang=en_us&edition=fundamental","pubTime":"2026-07-17 00:45","pubTimestamp":1784220325,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR, with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adlai-nortye-buy-rating-reaffirmed-as-dual-arm-an9025-strategy-advances-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adlai-nortye-buy-rating-reaffirmed-as-dual-arm-an9025-strategy-advances-20-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449998","title":"Adlai Nortye Doses First US Patient in Weekly Arm of Phase 1 AN9025 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449998","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449998?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:37","pubTimestamp":1784201836,"startTime":"0","endTime":"0","summary":"Adlai Nortye  said Thursday it has dosed the first patient in the US in the intermittent weekly dosing arm of its phase 1 trial evaluating AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations.The company said that intermittent dosing offers a differentiated approach and may widen the therapeutic window based on preclinical data.Adlai said it plans to share initial phase 1 dose escalation data in the first half of next year from the continuous once-daily arm of the study, with a potential early look at the once-weekly arm.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","BK4139","LU2133065610.SGD","IE00BZ199S13.USD","ANL","ALN","ANL.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}]}}